A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication
A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Phase 3 Trial to Evaluate the Safety and Efficacy of Dapagliflozin in Subjects With Type 2 Diabetes With Inadequately Controlled Hypertension on an Angiotensin-Converting Enzyme (ACE) Inhibitor or Angiotensin Receptor Blocker (ARB) and an Additional Antihypertensive Medication
The purpose of this study is to learn if BMS-512148 (Dapagliflozin), after 12 weeks, can improve (decrease) blood pressure in patients with type 2 diabetes with uncontrolled hypertension who are on an Angiotensin-converting enzyme inhibitor (ACEI) or an Angiotensin Receptor Blocker (ARB).The safety of this treatment will also be studied
Inclusion Criteria:
Exclusion Criteria:
North Massapequa, New York 11758, United States
Feasterville, Pennsylvania 19053, United States
Sugarland, Texas 77479, United States
Kelowona, British Columbia V1Y 3G8, Canada
Monction, New Brunswick E1G 1A7, Canada
Hyderabad, Andhra Pradesh 5000 18, India
Chennai Tamilnadu, 6000081, India
Distrito Federal, Mexico City 07020, Mexico
Del. Benito Juarez, 03100, Mexico
Fajard, 00738, Puerto Rico